NCT07309055

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 201 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.

Conditions

• Adolescents With Moderate-to-severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	SHR-1819 Injection	SHR-1819 injection.
DRUG	SHR-1819 Injection Placebo	SHR-1819 injection placebo.

Timeline

• Start date: 2026-03-21
• Primary completion: 2027-11-01
• Completion: 2027-12-01
• First posted: 2025-12-30
• Last updated: 2026-04-07

Locations

2 sites across 1 country: China